Gyre Therapeutics Appoints New CMO and CSO
Ticker: GYRE · Form: 8-K · Filed: Mar 21, 2024 · CIK: 1124105
| Field | Detail |
|---|---|
| Company | Gyre Therapeutics, Inc. (GYRE) |
| Form Type | 8-K |
| Filed Date | Mar 21, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, personnel
TL;DR
Gyre Therapeutics beefs up leadership with new CMO & CSO appointments.
AI Summary
Gyre Therapeutics, Inc. announced on March 20, 2024, the appointment of Dr. Jonathan M. Roth as Chief Medical Officer and Dr. David M. Chang as Chief Scientific Officer. The company also disclosed compensatory arrangements for these key officers, details of which are filed as exhibits to this report.
Why It Matters
The appointment of new Chief Medical and Scientific Officers signals a potential shift in the company's strategic direction and focus on research and development, which could impact its future drug pipeline and market position.
Risk Assessment
Risk Level: medium — The appointment of new senior leadership in R&D roles can introduce uncertainty regarding strategic direction and execution, potentially impacting the company's stock performance.
Key Players & Entities
- Gyre Therapeutics, Inc. (company) — Registrant
- Dr. Jonathan M. Roth (person) — Appointed Chief Medical Officer
- Dr. David M. Chang (person) — Appointed Chief Scientific Officer
- March 20, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as the new Chief Medical Officer at Gyre Therapeutics?
Dr. Jonathan M. Roth has been appointed as the new Chief Medical Officer.
Who has been appointed as the new Chief Scientific Officer at Gyre Therapeutics?
Dr. David M. Chang has been appointed as the new Chief Scientific Officer.
What is the date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 20, 2024.
What is the principal executive office address for Gyre Therapeutics?
The principal executive office is located at 12770 High Bluff Drive, Suite 150, San Diego, CA 92130.
What were Gyre Therapeutics' former names?
Gyre Therapeutics, Inc. was formerly known as Catalyst Biosciences, Inc. and Targacept Inc.
Filing Stats: 893 words · 4 min read · ~3 pages · Grade level 10.8 · Accepted 2024-03-21 07:15:51
Filing Documents
- ef20024709_8k.htm (8-K) — 32KB
- ef20024709_ex99-1.htm (EX-99.1) — 9KB
- image01.jpg (GRAPHIC) — 4KB
- 0001140361-24-014493.txt ( ) — 187KB
- gyre-20240320.xsd (EX-101.SCH) — 4KB
- gyre-20240320_lab.xml (EX-101.LAB) — 21KB
- gyre-20240320_pre.xml (EX-101.PRE) — 16KB
- ef20024709_8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The following exhibits are being furnished herewith: Exhibit Number Exhibit Title or Description 99.1 Press Release, dated March 21, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GYRE THERAPEUTICS, INC. Date: March 21, 2024 By: /s/ Ruoyu Chen Name: Ruoyu Chen Title: Chief Financial Officer